Financial & Business News

A new industry standard for faster, more precise and confident decision-making in private capital markets NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Kroll, the leading independent provider of global financial and risk advisory solutions, and StepStone Group (Nasdaq: STEP), a global private markets solutions provider, today announced the launch of the Kroll StepStone Private Credit Benchmarks (Benchmarks).

Vancouver, British Columbia – TheNewswire - September 8, 2025 – Juggernaut Exploration Ltd (JUGR.V) (OTCQB: JUGRF) (FSE: 4JE) ( the “Company” or “Juggernaut”) is excited to announce that it has identified 4 distinct extensive drill-ready gold-rich zones that remain wide open located along the prolific 15 km Highway of Gold Corridor within the Eldorado System, including: the Gold Dome Zone where grab samples assayed up to 256.60 g/t Au or 8.25 oz/t Au; the Gold Swarm Zone where grab samples assayed up to 226.94 g/t Au or 7.30 oz/t Au; the Big Mac Zone where grab samples assayed up to 111.35 g/t Au or 3.58 oz/t Au; and the Whopper Zone where grab samples assayed up to 39.84 g/t Au or 1.28 oz/t Au on the Big One property (the “Property”), Golden Triangle, British Columbia . The Company expanded the high-grade gold mineralized Eldorado System that hosts the Highway of Gold with >500 widespread mineralized veins covering an area of ~9 km 2 . The Big One discovery is located

A new industry standard for faster, more precise and confident decision-making in private capital markets A new industry standard for faster, more precise and confident decision-making in private capital markets

WILMINGTON, Ohio--(BUSINESS WIRE)--ATSG today announced the appointment of Greg Mays as President, responsible for leading ATSG's Commercial and Operations teams.

I reiterate my buy rating on JNJ, supported by steady EPS growth, robust free cash flow, and an attractive valuation. Recent quarterly results beat expectations, with management raising guidance and analysts issuing numerous EPS upgrades, reflecting strong operational momentum. Technically, JNJ has broken out of its downtrend, with rising moving averages and bullish momentum, targeting a fair value of $187.

Collaboration to accelerate financial inclusion across Indonesia and India via AI-optimized agent networks and financial inclusion. Jakarta, Indonesia & Mumbai, India--(Newsfile Corp. - September 8, 2025) - DigiAsia Corp. (NASDAQ: FAAS) ("DigiAsia" or the "Company"), a leading Indonesian fintech platform, and MOS Utility Limited (NSE: MOS) ("MOS"), a fintech innovator in India, today announced an expanded strategic partnership that extends beyond payments into branchless banking, AI-driven infrastructure, and financial inclusion solutions targeting a US$30+ billion opportunity.

Continue to observe a positive safety profile—no dose limiting toxicities, cytokine release syndrome or immune effector cell-associated neurotoxicity SAN JOSE, Calif. , Sept. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced it has completed dosing of the fourth cohort in its ongoing Phase 1 clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer.

The leading European asset manager specializing in digital assets with ~US$10 billion in AuM sets sights on expanding into U.S. market

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval Company continues preparations for enabling initiation of the Phase 3 study with the goal of advancing the study with a strategic partner early next year Company maintains previous guidance for completion of a strategic partnership with one of our advanced clinical assets this year SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced outcomes from its Type B meeting with the United States Food and Drug Administration (FDA).

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-world effectiveness of neffy is consistent with that historically reported for epinephrine injection SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today shares real-world evidence evaluating the clinical performance of neffy ® (epinephrine nasal spray) in patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy.